Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 356

1.

Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK.

Cross NCP, White HE, Evans PAS, Hancock J, Copland M, Milojkovic D, Mason J, Craine S, Mead AJ.

Br J Haematol. 2018 Sep;182(6):777-788. doi: 10.1111/bjh.15542. Epub 2018 Aug 20. Review.

2.

Absence of CALR Mutations in Idiopathic Erythrocytosis Patients with Low Serum Erythropoietin Levels.

Catherwood MA, Graham A, Cuthbert RJG, Garrec C, Gardie B, Girodon F, Laird S, Cross NCP, McMullin MF.

Acta Haematol. 2018;139(4):217-219. doi: 10.1159/000489006. Epub 2018 May 30. No abstract available.

PMID:
29847812
3.

Chronic neutrophilic leukemia.

Khoder A, Al Obaidi M, Babb A, Liu C, Cross NCP, Bain BJ.

Am J Hematol. 2018 Jun;93(6):841-842. doi: 10.1002/ajh.25073. Epub 2018 Mar 14. No abstract available.

PMID:
29473201
4.

Routine Screening for KIT M541L Is Not Warranted in the Diagnostic Work-Up of Patients with Hypereosinophilia.

Hoade Y, Metzgeroth G, Schwaab J, Reiter A, Cross NCP.

Acta Haematol. 2018;139(2):71-73. doi: 10.1159/000485959. Epub 2018 Jan 26. No abstract available.

PMID:
29393093
5.

Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis.

Naumann N, Jawhar M, Schwaab J, Kluger S, Lübke J, Metzgeroth G, Popp HD, Khaled N, Horny HP, Sotlar K, Valent P, Haferlach C, Göhring G, Schlegelberger B, Meggendorfer M, Hofmann WK, Cross NCP, Reiter A, Fabarius A.

Genes Chromosomes Cancer. 2018 May;57(5):252-259. doi: 10.1002/gcc.22526. Epub 2018 Feb 19.

PMID:
29341334
6.

A Novel PCM1-PDGFRB Fusion in a Patient with a Chronic Myeloproliferative Neoplasm and an ins(8;5).

Ghazzawi M, Mehra V, Knut M, Brown L, Tapper W, Chase A, de Lavallade H, Cross NCP.

Acta Haematol. 2017;138(4):198-200. doi: 10.1159/000484077. Epub 2017 Nov 24. No abstract available.

7.

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.

Harrison CN, Mead AJ, Panchal A, Fox S, Yap C, Gbandi E, Houlton A, Alimam S, Ewing J, Wood M, Chen F, Coppell J, Panoskaltsis N, Knapper S, Ali S, Hamblin A, Scherber R, Dueck AC, Cross NCP, Mesa R, McMullin MF.

Blood. 2017 Oct 26;130(17):1889-1897. doi: 10.1182/blood-2017-05-785790. Epub 2017 Aug 9.

8.

The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.

Yip BH, Steeples V, Repapi E, Armstrong RN, Llorian M, Roy S, Shaw J, Dolatshad H, Taylor S, Verma A, Bartenstein M, Vyas P, Cross NC, Malcovati L, Cazzola M, Hellström-Lindberg E, Ogawa S, Smith CW, Pellagatti A, Boultwood J.

J Clin Invest. 2017 Sep 1;127(9):3557. doi: 10.1172/JCI96202. Epub 2017 Sep 1. No abstract available.

9.

Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia.

Jawhar M, Naumann N, Knut M, Score J, Ghazzawi M, Schneider B, Kreuzer KA, Hallek M, Drexler HG, Chacko J, Wallis L, Fabarius A, Metzgeroth G, Hofmann WK, Chase A, Tapper W, Reiter A, Cross NCP.

Leukemia. 2017 Oct;31(10):2271-2273. doi: 10.1038/leu.2017.240. Epub 2017 Jul 28. No abstract available.

10.

Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.

Jawhar M, Naumann N, Schwaab J, Baurmann H, Casper J, Dang TA, Dietze L, Döhner K, Hänel A, Lathan B, Link H, Lotfi S, Maywald O, Mielke S, Müller L, Platzbecker U, Prümmer O, Thomssen H, Töpelt K, Panse J, Vieler T, Hofmann WK, Haferlach T, Haferlach C, Fabarius A, Hochhaus A, Cross NCP, Reiter A, Metzgeroth G.

Ann Hematol. 2017 Sep;96(9):1463-1470. doi: 10.1007/s00277-017-3067-x. Epub 2017 Jul 19.

PMID:
28725989
11.

Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms.

Rinke J, Müller JP, Blaess MF, Chase A, Meggendorfer M, Schäfer V, Winkelmann N, Haferlach C, Cross NCP, Hochhaus A, Ernst T.

Leukemia. 2017 Sep;31(9):1936-1943. doi: 10.1038/leu.2017.190. Epub 2017 Jun 19.

PMID:
28626218
12.

An unusual, activating insertion/deletion MPL mutant in primary myelofibrosis.

Defour JP, Hoade Y, Reuther AM, Callaway A, Ward D, Chen F, Constantinescu SN, Cross NCP.

Leukemia. 2017 Aug;31(8):1838-1839. doi: 10.1038/leu.2017.153. Epub 2017 May 22. No abstract available.

PMID:
28529309
13.

The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.

Silver RT, Barel AC, Lascu E, Ritchie EK, Roboz GJ, Christos PJ, Orazi A, Hassane DC, Tam W, Cross NCP.

Cancer. 2017 Jul 15;123(14):2680-2687. doi: 10.1002/cncr.30679. Epub 2017 May 18.

14.

The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.

Yip BH, Steeples V, Repapi E, Armstrong RN, Llorian M, Roy S, Shaw J, Dolatshad H, Taylor S, Verma A, Bartenstein M, Vyas P, Cross NC, Malcovati L, Cazzola M, Hellström-Lindberg E, Ogawa S, Smith CW, Pellagatti A, Boultwood J.

J Clin Invest. 2017 Jun 1;127(6):2206-2221. doi: 10.1172/JCI91363. Epub 2017 Apr 24. Erratum in: J Clin Invest. 2017 Sep 1;127(9):3557.

15.

Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers.

Jawhar M, Schwaab J, Naumann N, Horny HP, Sotlar K, Haferlach T, Metzgeroth G, Fabarius A, Valent P, Hofmann WK, Cross NCP, Meggendorfer M, Reiter A.

Blood. 2017 Jul 13;130(2):137-145. doi: 10.1182/blood-2017-01-764423. Epub 2017 Apr 19.

16.

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.

Giles FJ, Rea D, Rosti G, Cross NCP, Steegmann JL, Griskevicius L, le Coutre P, Coriu D, Petrov L, Ossenkoppele GJ, Mahon FX, Saussele S, Hellmann A, Koskenvesa P, Brümmendorf TH, Gastl G, Castagnetti F, Vincenzi B, Haenig J, Hochhaus A.

J Cancer Res Clin Oncol. 2017 Aug;143(8):1585-1596. doi: 10.1007/s00432-017-2402-x. Epub 2017 Mar 31.

17.

Evaluation of serum erythropoietin values as defined by 2016 World Health Organization criteria for the diagnosis of polycythemia vera.

Silver RT, Krichevsky S, Gjoni S, Cross NCP.

Leuk Lymphoma. 2017 Nov;58(11):2768-2769. doi: 10.1080/10428194.2017.1300892. Epub 2017 Mar 20. No abstract available.

PMID:
28317411
18.

Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia.

Gunawan AS, McLornan DP, Wilkins B, Waghorn K, Hoade Y, Cross NCP, Harrison CN.

Haematologica. 2017 Jun;102(6):e238-e240. doi: 10.3324/haematol.2017.163790. Epub 2017 Mar 16. No abstract available.

19.

Genomics of Myeloproliferative Neoplasms.

Zoi K, Cross NC.

J Clin Oncol. 2017 Mar 20;35(9):947-954. doi: 10.1200/JCO.2016.70.7968. Epub 2017 Feb 13. Review.

PMID:
28297629
20.

Measurement of BCR-ABL1 by RT-qPCR in chronic myeloid leukaemia: findings from an International EQA Programme.

Scott S, Travis D, Whitby L, Bainbridge J, Cross NCP, Barnett D.

Br J Haematol. 2017 May;177(3):414-422. doi: 10.1111/bjh.14557. Epub 2017 Mar 14.

PMID:
28295199

Supplemental Content

Loading ...
Support Center